Literature DB >> 18374050

Cognitive changes after parathyroidectomy in patients with secondary hyperparathyroidism.

Fong-Fu Chou1, Jin-Bor Chen, Kun-Chou Hsieh, Chia-Wei Liou.   

Abstract

BACKGROUND: Cognitive impairment was frequently reported in uremic patients with dialysis, but improvements of cognition after parathyroidectomy for symptomatic secondary hyperparathyroidism have never been reported before.
METHODS: Thirty-nine patients, who were successfully operated on with total parathyroidectomy plus autotransplantation were enrolled. Twenty-three dialysis patients, age >50 years, who had a serum level of intact parathyroid hormone (iPTH) greater than 650 pg/ml, and who did not undergo parathyroidectomy were selected as the control group. The mini-mental state examination (MMSE) and the clinical dementia rating (CDR) test were administered to all patients. Before the operation, educational level, symptoms of bone pain, skin itching, general weakness and insomnia were recorded and serum levels of calcium, phosphorus, alkaline phosphatase (Alk-ptase), iPTH, aluminum, and hemoglobin were measured in the study and control groups. At 12-week postoperatively, serum levels of calcium, phosphorus, Alk-ptase, iPTH, and aluminum were measured again and at 16-week postoperatively, the MMSE and the CDR test were administered again. In the control group, both MMSE and CDR test were administered again after the period or 16-week.
RESULTS: Serum calcium level was only significant difference (p = 0.002), whereas clinical symptoms, gender, etiologies of secondary hyperparathyroidism, duration of dialysis, educational level, age, and serum levels of phosphorus, Alk-ptase, iPTH, aluminum, and hemoglobin were not significantly different between the two groups. The educational level was the only factor affecting MMSE scores (p = 0.003). In the study group, at 12-week postoperatively, symptoms improved significantly, serum levels of calcium, phosphorus, Alk-ptase, iPTH, and aluminum decreased significantly, and at 16-week postoperatively, MMSE scores increased from 25 +/- 5 (mean +/- SD) to 26 +/- 5 (p < 0.001) and CDR scales decreased significantly (p < 0.001). Neither MMSE scores nor CDR scales of the control group changed significantly after the 16-week period.
CONCLUSION: Parathyroidectomy for symptomatic secondary hyperparathyroidism can improve cognition.

Entities:  

Mesh:

Year:  2008        PMID: 18374050     DOI: 10.1016/j.surg.2007.11.019

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  13 in total

1.  Low parathyroid hormone levels after parathyroidectomy reduce cardiovascular mortality in chronic hemodialysis patients.

Authors:  Noriyuki Iwamoto; Nodoka Sato; Masaya Nishida; Tetsuya Hashimoto; Hiroyuki Kobayashi; Satoru Yamazaki; Koji Okino; Masato Nishimura; Toru Takatani; Yu Okamoto; Tsuneyuki Nakanouchi; Masaki Koyama; Naoto Adachi; Kanji Ninomiya; Hisao Mabuchi; Kunitoshi Iseki
Journal:  Clin Exp Nephrol       Date:  2015-12-17       Impact factor: 2.801

Review 2.  Neuropsychiatric complications of chronic kidney disease.

Authors:  Rory McQuillan; Sarbjit V Jassal
Journal:  Nat Rev Nephrol       Date:  2010-06-22       Impact factor: 28.314

3.  Association between abnormal thalamic metabolites and sleep disturbance in patients with end-stage renal disease.

Authors:  Xueying Ma; Yan Zhang; Shaohui Ma; Peng Li; Dun Ding; Hua Liu; Jixin Liu; Ming Zhang
Journal:  Metab Brain Dis       Date:  2018-07-04       Impact factor: 3.584

4.  A Profile of Nanoparticle-Based Plasma Neurodegenerative Biomarkers for Cognitive Function Among Patients Undergoing Hemodialysis.

Authors:  Jin-Bor Chen; Chiung-Chih Chang; Sin-Hua Moi; Lung-Chih Li
Journal:  Int J Gen Med       Date:  2022-07-11

Review 5.  Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis.

Authors:  Yoshihiro Tominaga; Susumu Matsuoka; Nobuaki Uno
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

Review 6.  Parathyroid hormone, cognitive function and dementia: a systematic review.

Authors:  Ilianna Lourida; Jo Thompson-Coon; Chris M Dickens; Maya Soni; Elżbieta Kuźma; Katarina Kos; David J Llewellyn
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

Review 7.  Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease.

Authors:  Mathias Haarhaus; Dean Gilham; Ewelina Kulikowski; Per Magnusson; Kamyar Kalantar-Zadeh
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-01       Impact factor: 3.416

8.  Mutual Interaction of Clinical Factors and Specific microRNAs to Predict Mild Cognitive Impairment in Patients Receiving Hemodialysis.

Authors:  Jin-Bor Chen; Chiung-Chih Chang; Lung-Chih Li; Wen-Chin Lee; Chia-Ni Lin; Sung-Chou Li; Sin-Hua Moi; Cheng-Hong Yang
Journal:  Cells       Date:  2020-10-15       Impact factor: 6.600

9.  Parathyroidectomy improves survival in patients with severe hyperparathyroidism: a comparative study.

Authors:  Patricia Taschner Goldenstein; Rosilene Motta Elias; Lilian Pires de Freitas do Carmo; Fernanda Oliveira Coelho; Luciene Pereira Magalhães; Gisele Lins Antunes; Melani Ribeiro Custódio; Fábio Luiz de Menezes Montenegro; Silvia Maria Titan; Vanda Jorgetti; Rosa Maria Affonso Moysés
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

Review 10.  Parathyroid Hormone: A Uremic Toxin.

Authors:  Eduardo J Duque; Rosilene M Elias; Rosa M A Moysés
Journal:  Toxins (Basel)       Date:  2020-03-17       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.